All filters
Slidesets
Parasitic infections (Schistosomiasis infection, Liver flukes)- Edford Sinkala, BScHB, MBChB, MMed, PhD, FRCP
Presented at:
Conference on Liver Disease in Africa (COLDA) 2018
Slidesets
Fatty Liver disease- Mark Thursz, MRCP
Presented at:
Conference on Liver Disease in Africa (COLDA) 2018
Slidesets
Point-of-care testing for hepatitis B virus infection in a community-based occupational health cohort in the Western Cape Province, South Africa- Nafiisah Chotun
Presented at:
Conference on Liver Disease in Africa (COLDA) 2018
Slidesets
Management of Hepatocellular Carcinoma in Africa- Wendy Spearman, MBChB, FCP, FRCP, MMed, PhD
Presented at:
Conference on Liver Disease in Africa (COLDA) 2018
Slidesets
Large-scale discovery and validation of blood and urinary discriminant metabolites as potential biomarkers for the diagnosis hepatocellular carcinoma in West Africa -Mei Ran Abellona
Presented at:
Conference on Liver Disease in Africa (COLDA) 2018
Slidesets
Management of end-stage Liver Disease in Resource Limited Settings- Mark Sonderup
Presented at:
Conference on Liver Disease in Africa (COLDA) 2018
Slidesets
The establishment of hepatitis B care and treatment clinics in the United Republic of Tanzania: A demonstration project following WHO guidelines- John Rwegasha
Presented at:
Conference on Liver Disease in Africa (COLDA) 2018
Slidesets
New diagnostics to improve diagnosis of liver disease- Francesco Marinucci
Presented at:
Conference on Liver Disease in Africa (COLDA) 2018
Slidesets
NOhep Visionaries in Africa: Medical professionals leading the way towards hepatitis elimination- Jessica Hicks
Presented at:
Conference on Liver Disease in Africa (COLDA) 2018
Slidesets
Integrating science, logistics and cost in approval of hierarchical testing strategies for NASH - The payer's perspective- Robert LoNigro, MD
Presented at:
International Workshop on NASH Biomarkers 2018
Slidesets
Pathways and priorities for biomarker assessment- Peter Stein, MD
Presented at:
International Workshop on NASH Biomarkers 2018
Slidesets
Repeatability, reproducibility and analytic standards for biomarker development- Abbas Bandukwala
Presented at:
International Workshop on NASH Biomarkers 2018
Slidesets
Linking “intended use” to evidence needed for bringing a biomarker to market- John Sninsky, PhD
Presented at:
International Workshop on NASH Biomarkers 2018
Slidesets
Reporting standards: STARD & TRIPOD- Patrick Bossuyt, PhD
Presented at:
International Workshop on NASH Biomarkers 2018
Slidesets
Quality standards for imaging studies- Claude Sirlin, MD
Presented at:
International Workshop on NASH Biomarkers 2018
Slidesets
Case definitions for use as reference standards- Mohammed Siddiqui, MD
Presented at:
International Workshop on NASH Biomarkers 2018
Slidesets
Defining the reference standard for biomarker development - Histology versus clinical outcomes- Kathleen Donohue, MD
Presented at:
International Workshop on NASH Biomarkers 2018
Slidesets
A Context of Use Framework for Bioanalytical Validation of the CK18 Apoptosis Biomarker for NASH Drug Development- Sumit Kar
Presented at:
International Workshop on NASH Biomarkers 2018
Slidesets
Serum markers of collagen formation are associated with the severity of Liver fibrosis and Non-Alcoholic Steatohepatitis (NASH) histological features and to impaired renal function (IRF) in a NAFLD cohort- Samuel Daniels
Presented at:
International Workshop on NASH Biomarkers 2018
Slidesets
What is needed to link device approval to clinical application approval?- David Litwack, PhD
Presented at:
International Workshop on NASH Biomarkers 2018
Slidesets
Algorithm to identify non-alcoholic steatohepatitis (NASH) patients with a NAS≥4 and F≥2: algorithm derived in an American screening cohort and validation in a British non-alcoholic fatty liver disease (NAFLD) cohort- Celine Fournier
Presented at:
International Workshop on NASH Biomarkers 2018
Slidesets
Study design to validate biomarkers of therapeutic response for pre-cirrhotic NASH- Brent Tetri, MD
Presented at:
International Workshop on NASH Biomarkers 2018
Slidesets
Study design to validate biomarkers of therapeutic response in cirrhosis due to NASH- Detlef Schuppan, MD, PhD
Presented at:
International Workshop on NASH Biomarkers 2018